MPM BioImpact, a biotechnology investment firm creating and investing in innovative companies seeking to deliver ...

Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve ...

Raises 2025 Financial Guidance Ranges for Total Revenue to $1,150 - $1,225 million, Representing YoY Growth of 16% - 23%, Adjusted EBITDA of $755 - $805 million, Representing YoY Growth of 24% - 32%, ...

CHICAGO-PRovoke Media's North American Summit-including the In2 SABRE Awards-is returning to Chicago as a standalone event ...

The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type ...

Bristol Myers Squibb’s Cobenfy achieved an 8.4-point PANSS improvement over placebo after five weeks in a phase 3 trial that ...

Cambridge Cognition Holdings plc (AIM: COG), the brain health software group, congratulates Bristol Myers Squibb, the global biopharmaceutical company, for its recent FDA approval of Cobenfy (KarXT™ ...

Global Brain Ischemia market Size, Share & Trends Analysis Report By treatment (Angioplasty, Beta Blockers, Angiotensin-Converting Enzyme (ACE) In ...

Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON, Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading ...

Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...

Children’s doctors with Norton Healthcare provide health and safety tips for families and kids during dangerous cold and ...